Hims jumps after RFK Jr. announces FDA may loosen regulations for 12 peptides
rose more than 13% on Wednesday and continued to rise in premarket trading on Thursday after Health Secretary Robert F. Kennedy Jr. said that the Food and Drug Administration may ease restrictions on ...
Eli Lilly makes the world’s bestselling drug. Can it keep the party going?
Eli Lilly, the most valuable pharmaceutical company in the world , has made a killing selling diabetes and weight-loss drugs that are widely viewed as the most effective in the market. But as the GLP-...
FDA clarifies stricter stance on GLP-1 compounding: Reuters
The Food and Drug Administration reiterated its increasingly strict stance on compounded versions of GLP-1s, Reuters reported Wednesday. The FDA said that outside of drug shortages, “routine productio...
The FDA is expected to lift restrictions on certain peptides, the NYT reports
The Food and Drug Administration is expected to lift restrictions on certain peptides, allowing the experimental, often injectable substances to be sold by compounding pharmacies, The New York Times r...
Novo says FDA has approved high-dose Wegovy shot
The Food and Drug Administration approved high-dose Wegovy shot, the company announced on Thursday. Wegovy HD, a once-weekly 7.2-milligram injection, helped patients lose 20.7% of their body weight a...
Lilly reports encouraging trial results for its next-gen GLP-1 shot
released late-stage trial results for its next-generation GLP-1 shot, retatrutide, showing the drug helped patients lose more weight than anything currently on the market. Patients taking the highest ...
Eli Lilly receives its only sell rating as HSBC downgrades, citing smaller market for weight-loss drugs
slipped in early trading after analysts at HSBC gave the pharmaceutical darling at the center of the obesity drug boom a rare downgrade. Analysts at the bank cut their rating to “reduce” from “hold.” ...
Hims continues to rise on analyst upgrades following its Novo Nordisk partnership
Shares of telehealth company climbed Tuesday as analysts upgraded the stock following the Monday announcement of its landmark deal with Wegovy maker . Shares were recently up 12%. Citi upgraded Hims ...
Hims surges after Novo Nordisk reportedly ends feud, agrees to sell its weight-loss drugs on the platform
is soaring in premarket trading, up around 54% as of 6 a.m. ET, after reports that the telehealth company will announce a new partnership with Novo Nordisk to sell the latter’s weight-loss drugs on it...
Moderna jumps after settling Covid vaccine patent dispute
is up 4.8% at 5 a.m. ET in premarket trading after the pharma giant said on Tuesday that it had reached a deal to resolve a patent dispute related to the technology behind its key Covid vaccine models...
Hims & Hers surges after RFK Jr. tells Joe Rogan he’s hoping to make peptides more accessible
is spiking on Monday amid some remarks that Health and Human Services Secretary Robert F. Kennedy Jr. made on the “Joe Rogan Experience” podcast . At around the 1.5-hour mark of the podcast, RFK Jr. i...
How GLP-1s elevated Hims — and brought it back down to earth
executives spent much of its Monday earnings report assuring investors that the company is more than knockoff weight-loss drugs, a product line that has stimulated growth in recent years but also stir...
Novo Nordisk to slash GLP-1 list prices starting in 2027
, under pressure from fierce competition, said it would slash the list prices of its GLP-1 drugs by up to 50% starting next year. The company announced Tuesday that it would slash the list prices for ...
Novo Nordisk sinks after its experimental obesity drug falls short of Eli Lilly’s in head-to-head trial
sank after the newest generation of its weight-loss shot, CagriSema, failed to show it was more effective than tirzepatide, the weight-loss and diabetes drug sold by . In a head-to-head trial, patient...
Grail tanks after cancer detection test fails in key study
A blood test for detecting cancer early that was indirectly advertised at the Super Bowl failed in a major study. , the diagnostics company developing the test, Galleri, announced top-line results of ...
Exclusive: Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators
Arizona state regulators had already raised concerns about the compounding practices of the pharmacy behind Hims & Hers’ short-lived copy of Novo Nordisk’s Wegovy pill. Now, state officials are lookin...
Moderna reports Q4 earnings beat, upbeat 2026 outlook
reported Q4 earnings results on Friday that beat Wall Street estimates and also gave cheery full-year sales guidance for 2026, which comes as the company faces major regulatory headwinds. For the last...
Options trades to play for a short squeeze in Hims & Hers as the pain piles up
has been clobbered over the past week as the telehealth company stepped back from plans to sell a copycat version of weight-loss pill and then faced a lawsuit from the Danish pharma titan. In these t...
Gilead rises after earnings beat driven by HIV drug sales
rose more than 5% on Wednesday after it reported quarterly earnings and revenue that beat Wall Street estimates, driven by sales of its HIV drugs. For the last three months of 2025, Gilead reported: A...
Novo Nordisk has lost most of its post-Wegovy market cap gains
Danish pharma giant has now erased nearly all of the market cap gains it racked up after winning FDA approval for its weight-loss drug Wegovy in 2021. The company’s shares slid ~20% last week amid tw...